Floatz logo

Dordaviprone

H3 K27M Glioma

Jazz PharmaceuticalsSmall moleculePhase 2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the H3 K27M Glioma cohort.

Asset / SponsorPhaseRating
Ribociclib
Nationwide Children's Hospital
Phase 2B
Everolimus
Nationwide Children's Hospital
Phase 2CCC
Olutasidenib
Rigel Pharmaceuticals
Phase 2CCC
Pegargiminase
Sabine Mueller, MD, PhD
Phase 1/2CC
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

Dordaviprone is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →